Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates

Nurix Therapeutics reported an earnings surprise of -4.22% and a revenue surprise of -57.21% for the quarter ended February 2026, with revenue missing expectations by a very large margin. The sharp revenue shortfall suggests meaningful commercialization or operational setbacks that could prompt downward revisions to estimates and pressure the stock. The modest EPS miss versus the massive revenue miss implies cost offsets or one-time items, but the revenue weakness is the dominant concern for valuation and near-term sentiment.

Analysis

Nurix Therapeutics reported an earnings surprise of -4.22% and a revenue surprise of -57.21% for the quarter ended February 2026, with revenue missing expectations by a very large margin. The sharp revenue shortfall suggests meaningful commercialization or operational setbacks that could prompt downward revisions to estimates and pressure the stock. The modest EPS miss versus the massive revenue miss implies cost offsets or one-time items, but the revenue weakness is the dominant concern for valuation and near-term sentiment.